Status:
COMPLETED
A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function
Lead Sponsor:
Pfizer
Conditions:
Hepatic Insufficiency
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function...
Eligibility Criteria
Inclusion
- Healthy volunteers who have normal liver function, and subjects who have either mild or moderate liver impairment.
Exclusion
- Subjects with severe liver impairment
- Subjects who have weakened immune systems
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00969813
Start Date
November 1 2009
End Date
January 1 2010
Last Update
February 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
South Miami, Florida, United States, 33143